Clinical uses of cannabis and Catha edulis products
dc.Affiliation | October University for modern sciences and Arts MSA | |
dc.contributor.author | Shahira M. Ezzat | |
dc.contributor.author | Passent M. Abdel Baki | |
dc.contributor.author | Rana M. Ibrahim | |
dc.contributor.author | Doaa Abu Elezz | |
dc.contributor.author | Mahmoud Abdelaziz | |
dc.contributor.author | Mohamed A. Salem | |
dc.date.accessioned | 2024-11-18T09:23:11Z | |
dc.date.available | 2024-11-18T09:23:11Z | |
dc.date.issued | 2024-01-01 | |
dc.description.abstract | The medicinal use of cannabis (Cannabis sativa) and khat (Catha edulis) as well as their products has been increased in the last decade. Medical cannabis and khat have been legalized in several countries. Additionally, the major cannabinoids, particularly cannabidiol and tetrahydrocannabinol, have been utilized for the development of FDA-approved pharmaceuticals. The clinical applications of cannabis and C. edulis products are complicated by legislation and regulations that are varied among countries. In this chapter, the pharmacological and the side effect profiles for the clinical uses of cannabis and C. edulis products are highlighted. Although, the clinical data for their use are continuing to evolve, the legal status needs to be authorized to keep the balance between clinical applications and limitations. | |
dc.identifier.citation | Ezzat, S. M., Baki, P. M. A., Ibrahim, R. M., Elezz, D. A., Abdelaziz, M., & Salem, M. A. (2024). Clinical uses of cannabis and Catha edulis products. In Elsevier eBooks (pp. 595–628). https://doi.org/10.1016/b978-0-323-95927-8.00028-1 | |
dc.identifier.doi | https://doi.org/10.1016/b978-0-323-95927-8.00028-1 | |
dc.identifier.other | https://doi.org/10.1016/b978-0-323-95927-8.00028-1 | |
dc.identifier.uri | https://repository.msa.edu.eg/handle/123456789/6250 | |
dc.language.iso | en_US | |
dc.publisher | Elsevier | |
dc.relation.ispartofseries | Cannabis and Khat in Drug Discovery: the Discovery Pipeline and the Endocannabinoid System ; Pages 595 - 6281 January 2024 | |
dc.subject | cannabis | |
dc.subject | cardiovascular disease | |
dc.subject | cellular process | |
dc.subject | clinical history finding | |
dc.subject | clinical trials side effects | |
dc.subject | cognitive process | |
dc.subject | cognitive psychology | |
dc.subject | drug | |
dc.subject | drug development | |
dc.subject | Khat | |
dc.subject | legal use | |
dc.subject | medicine | |
dc.subject | mental disorder | |
dc.subject | nervous system | |
dc.subject | nervous system disorder | |
dc.subject | neuroscience | |
dc.subject | organic compound | |
dc.subject | pain | |
dc.subject | pharmaceutical therapy | |
dc.subject | pharmacological parameter | |
dc.subject | pharmacology | |
dc.subject | pharmacology discipline | |
dc.subject | psychological disorders | |
dc.subject | therapeutic procedure | |
dc.subject | toxicity | |
dc.title | Clinical uses of cannabis and Catha edulis products | |
dc.type | Article |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- IMG-20231214-WA0000.jpg
- Size:
- 16.8 KB
- Format:
- Joint Photographic Experts Group/JPEG File Interchange Format (JFIF)
License bundle
1 - 1 of 1
No Thumbnail Available
- Name:
- license.txt
- Size:
- 51 B
- Format:
- Item-specific license agreed upon to submission
- Description: